What is the ideal treatment for advanced non-small-cell lung cancer with PD-L1 level ≥50%? Is mono immunotherapy enough?

被引：0

作者：

Bilgin, Burak ^{[1
]}

Yucel, Sebnem ^{[1
]}

Sendur, Mehmet Ali Nahit ^{[1
]}

Yalcin, Bulent ^{[1
]}

机构：

[1] Ankara Yildirim Beyazit Univ, Ankara Bilkent City Hosp, Dept Med Oncol, TR-06800 Ankara, Turkiye

来源：

FUTURE ONCOLOGY | 2024年 / 20卷 / 38期

关键词：

atezolimuzmab; cemiblimab; chemotherapy; first line; immune-checkpoint inhibition; lung cancer; PD-L1; pembrolizumab; 1ST-LINE PEMBROLIZUMAB; CEMIPLIMAB MONOTHERAPY; EXPRESSION; OUTCOMES; MULTICENTER;

D O I：

10.1080/14796694.2024.2414731

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3039 / 3041

页数：3

共 15 条

[1] Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression [J].

Aguilar, E. J. ;

Ricciuti, B. ;

Gainor, J. F. ;

Kehl, K. L. ;

Kravets, S. ;

Dahlberg, S. ;

Nishino, M. ;

Sholl, L. M. ;

Adeni, A. ;

Subegdjo, S. ;

Khosrowjerdi, S. ;

Peterson, R. M. ;

Digumarthy, S. ;

Liu, C. ;

Sauter, J. ;

Rizvi, H. ;

Arbour, K. C. ;

Carter, B. W. ;

Heymach, J. V. ;

Altan, M. ;

Hellmann, M. D. ;

Awad, M. M. .

ANNALS OF ONCOLOGY, 2019, 30 (10) :1653-1659

[2]

Akinboro O, 2022, J CLIN ONCOL, V40

[3] Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study [J].

Boyer, Michael ;

Sendur, Mehmet A. N. ;

Rodriguez-Abreu, Delvys ;

Park, Keunchil ;

Lee, Dae Ho ;

Cicin, Irfan ;

Yumuk, Perran Fulden ;

Orlandi, Francisco J. ;

Leal, Ticiana A. ;

Molinier, Olivier ;

Soparattanapaisarn, Nopadol ;

Langleben, Adrian ;

Califano, Raffaele ;

Medgyasszay, Balazs ;

Hsia, Te-Chun ;

Otterson, Gregory A. ;

Xu, Lu ;

Piperdi, Bilal ;

Samkari, Ayman ;

Reck, Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (21) :2327-+

[4] Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non small-cell lung cancer: The global, multicenter EXPRESS study [J].

Dietel, M. ;

Savelov, N. ;

Salanova, R. ;

Micke, P. ;

Bigras, G. ;

Hida, T. ;

Antunez, J. ;

Skov, B. Guldhammer ;

Hutarew, G. ;

Sua, L. F. ;

Akita, H. ;

Chan, O. S. H. ;

Piperdi, B. ;

Burke, T. ;

Khambata-Ford, S. ;

Deitz, A. C. .

LUNG CANCER, 2019, 134 :174-179

[5] Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy [J].

Ge, Wenzhen ;

Wu, Ning ;

Jalbert, Jessica J. ;

Quek, Ruben G. W. ;

Liu, Jinjie ;

Rietschel, Petra ;

Pouliot, Jean-Francois ;

Harnett, James ;

Hsu, Melinda Laine ;

Feliciano, Josephine L. .

CANCER MANAGEMENT AND RESEARCH, 2022, 14 :3191-3202

[6] Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC [J].

Herbst, Roy S. ;

Giaccone, Giuseppe ;

de Marinis, Filippo ;

Reinmuth, Niels ;

Vergnenegre, Alain ;

Barrios, Carlos H. ;

Morise, Masahiro ;

Felip, Enriqueta ;

Andric, Zoran ;

Geater, Sarayut ;

Ozguroglu, Mustafa ;

Zou, Wei ;

Sandler, Alan ;

Enquist, Ida ;

Komatsubara, Kimberly ;

Deng, Yu ;

Kuriki, Hiroshi ;

Wen, Xiaohui ;

McCleland, Mark ;

Mocci, Simonetta ;

Jassem, Jacek ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (14) :1328-1339

[7]

Kilickap S, 2021, J THORAC ONCOL, V16, pS101

[8] Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial [J].

Mok, Tony S. K. ;

Wu, Yi-Long ;

Kudaba, Iveta ;

Kowalski, Dariusz M. ;

Cho, Byoung Chul ;

Turna, Hande Z. ;

Castro, Gilberto, Jr. ;

Srimuninnimit, Vichien ;

Laktionov, Konstantin K. ;

Bondarenko, Igor ;

Kubota, Kaoru ;

Lubiniecki, Gregory M. ;

Zhang, Jin ;

Kush, Debra ;

Lopes, Gilberto .

LANCET, 2019, 393 (10183) :1819-1830

[9] First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a multicentre, open-label, randomised, phase 3 trial [J].

Ozguroglu, Mustafa ;

Kilickap, Saadettin ;

Sezer, Ahmet ;

Gumus, Mahmut ;

Bondarenko, Igor ;

Gogishvili, Miranda ;

Nechaeva, Marina ;

Schenker, Michael ;

Cicin, Irfan ;

Ho, Gwo Fuang ;

Kulyaba, Yaroslav ;

Zyuhal, Kasimova ;

Scheusan, Roxana-Ioana ;

Garassino, Marina Chiara ;

He, Xuanyao ;

Kaul, Manika ;

Okoye, Emmanuel ;

Li, Yuntong ;

Li, Siyu ;

Pouliot, Jean-Francois ;

Seebach, Frank ;

Lowy, Israel ;

Gullo, Giuseppe ;

Rietschel, Petra .

LANCET ONCOLOGY, 2023, 24 (09) :989-1001

[10] Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials [J].

Pathak, Ranjan ;

De Lima Lopes, Gilberto ;

Yu, Han ;

Aryal, Madan Raj ;

Ji, Wenyan ;

Frumento, Katherine Stemmer ;

Wallis, Christopher J. D. ;

Klaassen, Zachary ;

Park, Henry S. ;

Goldberg, Sarah B. .

CANCER, 2021, 127 (05) :709-719

← 1 2 →